ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0267

Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register

Juan Molina1, Fernando Sanchez-Alonso2, Cristina Bohorquez3, Cesar Diaz-Torne4, Carolina Perez-Garcia5, Juan Maria Blanco-Madrigal6, Paloma Vela-Casampere7, José María Älvaro-Gracia1 and Isabel Castrejon8, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, 3University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 4Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Department of Rheumatology, Hospital del Mar, Barcelona, Spain, 6Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, 7Hospital General Universitario Alicante, Alicante, Spain, 8Hospital Universitario Gregorio Marañón, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Biologicals, Joint Structure, rheumatoid arthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Session Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: To investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancy treated with biologic and targeted synthetic DMARDs (b/tsDMARDs)

Methods: Cohort study of patients included in BIOBADASER 3.0 up to 2021, treated with b/tsDMARDs and history of previous malignancy. Incident cancer was defined as any cancer (new primaries, local recurrence or metastases) during the drug exposure leading to therapy discontinuation. Incidence rates ratios of cancer per 1,000 patients-year (PY) and 95% confidence interval (CI) were estimated. Rates of incident cancer in tsDMARDs and other bDMARDs versus TNFi were compared.

Results: A total of 352 patients over 9,129 patients from BIOBADASER 3.0 had history of previous malignancy. Overall, there were 32 incident malignancies (17 solid cancer, 14 non-melanoma skin cancer and 1 melanoma) (Figure 1). Baseline characteristics of patients are shown in Table 1. The overall rate of incident malignancy was 27.1 (95% CI 18.6-38.3) events/1,000 PY, ranging between none events/1000 PY in the anti-IL17 group to 51.7 events/1000 PY in the anti-CTLA-4 group (Table 2). The overall rate of incident cancer did not differ significantly in patients exposed to JAKi [0.6 (95% CI 0.1-2.5)], anti-CD20 [0.3 (95% CI 0.1-1.4)], anti-IL6 [1.2 (95% CI 0.5-3.4)] or anti-CTLA-4 [1.3 (95% CI 0.5-3.6) versus TNFi therapy. The rate of different types of cancer (melanoma, non-melanoma skin cancer or solid tumors) did not differ between the different treatment groups when compared to TNFi.

Conclusion: The risk of incident cancer in patients with rheumatic diseases and previous malignancy did not differ between TNFi or other b/tsDMARDs

Supporting image 1

Table 1. Baseline characteristics of patients with prior malignancy with exposure to bDMARDs and tsDMARDs

Supporting image 2

Table 2. Rate and type of incident cancer in patients with prior malignancy with exposure to bDMARDs and tsDMARDs

Supporting image 3

Figure 1. Flowchart of patients included in the study.


Disclosures: J. Molina, None; F. Sanchez-Alonso, None; C. Bohorquez, None; C. Diaz-Torne, None; C. Perez-Garcia, None; J. Blanco-Madrigal, None; P. Vela-Casampere, None; J. Älvaro-Gracia, None; I. Castrejon, None.

To cite this abstract in AMA style:

Molina J, Sanchez-Alonso F, Bohorquez C, Diaz-Torne C, Perez-Garcia C, Blanco-Madrigal J, Vela-Casampere P, Älvaro-Gracia J, Castrejon I. Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cancer-risk-with-biologic-and-targeted-synthetic-dmards-in-patients-with-rheumatic-diseases-and-previous-malignancy-results-from-the-biobadaser-register/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cancer-risk-with-biologic-and-targeted-synthetic-dmards-in-patients-with-rheumatic-diseases-and-previous-malignancy-results-from-the-biobadaser-register/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences